Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study (Q81570219)

From Wikidata

Jump to navigation Jump to search

scientific article published on 02 December 2005

Language	Label	Description	Also known as
English	Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study	scientific article published on 02 December 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

phase II clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Gynecologic Oncology Group

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

Maurie Markman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

John Blessing

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

Stephen C Rubin

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

Joseph Connor

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

Parviz Hanjani

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

Steven Waggoner

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

publication date

2 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

101

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

436-440

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Second-line treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Redefining the target: chemotherapeutics as antiangiogenics

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Paclitaxel (taxol)

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2005.10.036

7 January 2021

Identifiers

10.1016/J.YGYNO.2005.10.036

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325893 AND SRC:MED&resulttype=core&format=json

10 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q81570219&oldid=1948702390"